Jared Ham
Research Subjects
Jared Ham has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Alejandro Lopez Cohen
Department of Graduate Medical Education, Memorial Hospital West, Pembroke Pines, FL 33028, USA
1 shared publication - Diana Carolina Andrade
Medical Science Liaison, AbbVie (Memorial Hospital West), Pompano Beach Florida
1 shared publication - Jayesh Parmar
Department of Clinical and Administrative Sciences, Larkin College of Pharmacy, Miami, FL 33169, USA
1 shared publication - Kyle Brown
Department of Pharmacy, Memorial Hospital West, Pembroke Pines, FL 33028, USA
1 shared publication - Leon Melnitsky
Memorial Healthcare System, Department of Emergency Medicine, Hollywood, Florida
1 shared publication - Vanessa Huffman
Department of Pharmacy, Memorial Hospital West, Memorial Healthcare System, Pembroke Pines, FL
1 shared publication
Latest Publications
- Open Access
Impact of Nasal Swabs on Empiric Treatment of Respiratory Tract Infections (INSERT-RTI)
Methicillin-resistant Staphylococcus aureus (MRSA) polymerase-chain-reaction nasal swabs (PCRNS) are a rapid diagnostic tool with a high negative predictive value. A PCRNS plus education “bundle” was implemented to inform clinicians on the utility of PCRNS for anti-MRSA therapy de-escalation in respiratory tract infections (RTI). The study included patients started on vancomycin with a PCRNS order three months before and after bundle implementation. The primary objective was the difference in duration of anti-MRSA therapy (DOT) for RTI. Secondary objectives included hospital length of stay (LOS), anti-MRSA therapy reinitiation, 30-day readmission, in-hospital mortality, and cost. We analyzed 62 of 110 patients screened, 20 in the preintervention and 42 in the postintervention arms. Mean DOT decreased after bundle implementation by 30.3 h (p = 0.039); mean DOT for patients with a negative PCRNS decreased by 39.7 h (p = 0.014). Median cost was lower after intervention [USD$51.69 versus USD$75.30 (p < 0.01)]. No significant difference in LOS, mortality, or readmission existed. The bundle implementation decreased vancomycin therapy and cost without negatively impacting patient outcomes.
Open AccessImpact of Nasal Swabs on Empiric Treatment of Respiratory Tract Infections (INSERT-RTI)
Methicillin-resistant Staphylococcus aureus (MRSA) polymerase-chain-reaction nasal swabs (PCRNS) are a rapid diagnostic tool with a high negative predictive value. A PCRNS plus education “bundle” was implemented to inform clinicians on the utility of PCRNS for anti-MRSA therapy de-escalation in respiratory tract infections (RTI). The study included patients started on vancomycin with a PCRNS order three months before and after bundle implementation. The primary objective was the difference in duration of anti-MRSA therapy (DOT) for RTI. Secondary objectives included hospital length of stay (LOS), anti-MRSA therapy reinitiation, 30-day readmission, in-hospital mortality, and cost. We analyzed 62 of 110 patients screened, 20 in the preintervention and 42 in the postintervention arms. Mean DOT decreased after bundle implementation by 30.3 h (p = 0.039); mean DOT for patients with a negative PCRNS decreased by 39.7 h (p = 0.014). Median cost was lower after intervention [USD$51.69 versus USD$75.30 (p < 0.01)]. No significant difference in LOS, mortality, or readmission existed. The bundle implementation decreased vancomycin therapy and cost without negatively impacting patient outcomes.